Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Drops Development of TAK-264, TAK-272
November 2, 2015
- Sakigake Designation System Very Useful: Astellas President
November 2, 2015
- Eisai Squeezes Out Sales Rise on Growing Global Brands
November 2, 2015
- Daiichi Sankyo’s Half-Year Revenue Up 11% Due to Growth in Sales in Japan and US; Operating Profit Up 61%
November 2, 2015
- Xtandi Makes Strong Contribution to Astellas’s Half-Year Sales and Profits
November 2, 2015
- Entyvio’s Sales Jump Underpins Takeda’s Half-Year Revenue
November 2, 2015
- Shionogi Delivers Record Profits in April-September on Brisk HIV Franchise
October 30, 2015
- Sakigake Designated Anticancer Agent ASP2215 Enters Multinational PIII Study: Astellas
October 30, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Logs Rise in Half-Year Earnings on N. America Latuda Sales, Weak Yen
October 29, 2015
- DPT-IPV Vaccine Quattrovac to Be Out of Stock in November
October 29, 2015
- Yakult Licenses Novel Platelet Increasing Agent from Nissan Chemical
October 28, 2015
- Lupin Names Fabrice Egros As President of Asia Pacific, Japan Operations
October 28, 2015
- Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
- Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
- Lilly Joins NCC’s SCRUM-Japan Genomic Screening Project
October 26, 2015
- GSK to Transfer 3 Oncology Products to Novartis in Japan in November
October 26, 2015
- Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
October 23, 2015
- Chugai to Build New Antibody API Manufacturing Plant
October 23, 2015
- Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…